- Home
- BTAI vs IMRN Comparison
BTAI vs IMRN Comparison
Compare BTAI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- IMRN
- Stock Information
- Founded
- BTAI 2017
- IMRN 1994
- Country
- BTAI United States
- IMRN Australia
- Employees
- BTAI N/A
- IMRN N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- IMRN Health Care
- Exchange
- BTAI Nasdaq
- IMRN Nasdaq
- Market Cap
- BTAI 8.3M
- IMRN 9.2M
- IPO Year
- BTAI 2018
- IMRN N/A
- Fundamental
- Price
- BTAI $1.86
- IMRN $1.70
- Analyst Decision
- BTAI Buy
- IMRN Strong Buy
- Analyst Count
- BTAI 5
- IMRN 1
- Target Price
- BTAI $34.60
- IMRN $5.00
- AVG Volume (30 Days)
- BTAI 295.5K
- IMRN 24.0K
- Earning Date
- BTAI 08-05-2025
- IMRN 07-07-2025
- Dividend Yield
- BTAI N/A
- IMRN N/A
- EPS Growth
- BTAI N/A
- IMRN N/A
- EPS
- BTAI N/A
- IMRN N/A
- Revenue
- BTAI $1,852,000.00
- IMRN $4,048,286.00
- Revenue This Year
- BTAI $5.03
- IMRN N/A
- Revenue Next Year
- BTAI $291.01
- IMRN N/A
- P/E Ratio
- BTAI N/A
- IMRN N/A
- Revenue Growth
- BTAI 5.47
- IMRN 82.90
- 52 Week Low
- BTAI $1.17
- IMRN $1.50
- 52 Week High
- BTAI $21.92
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- BTAI 56.60
- IMRN 35.44
- Support Level
- BTAI $1.69
- IMRN $1.82
- Resistance Level
- BTAI $2.08
- IMRN $1.96
- Average True Range (ATR)
- BTAI 0.21
- IMRN 0.11
- MACD
- BTAI 0.02
- IMRN -0.01
- Stochastic Oscillator
- BTAI 57.89
- IMRN 7.50
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.